The BioMAP® Platform provides an unbiased, target-agnostic and data-driven approach to understanding the effect of mono- or combination therapies on human disease models and translational biomarkers. Validated with clinically approved drugs and known test agents, the BioMAP Platform is powered by human primary cultures or co-cultures stimulated to recapitulate specific disease states and qualified with clinically approved and investigative test agents, a Reference Database of over 4,500+ molecules, data analytics, and expert interpretation to provide clients with actionable insights.
BioMAP Human Primary Cell Disease Models
Figure. The BioMAP Platform provides superior and standardized human disease models spanning a broad scope of tissue and disease biology, with human primary cell types co-cultured and stimulated to re-capitulate complex disease-relevant environments. The three pillars of the BioMAP Platform include BioMAP systems (shown here), the comprehensive BioMAP Reference Database of over 4,500 compounds, and advanced data analytics. The BioMAP Platform supports phenotypic drug discovery across several areas of human disease biology in a robust and medium throughput screening-format to enable unbiased discovery of molecules relevant to biological outcomes. Profiling test agents in this platform provides translational insights on mechanisms-of-action, efficacy, and safety related pharmacology; identifies potential response biomarkers; and helps with indication and dosing guidance. Shown here is a schematic of BioMAP systems composed of human primary cells pooled from healthy donors, in mono- or co-culture conditions, stimulated to capture the complexity of human disease biology.
BioMAP profiling is the broadest, most physiologically relevant method to quickly and robustly determine the efficacy, safety, and mechanism-of-action of candidate drugs or test molecules to support decisions on pipeline progression. The BioMAP Platform offers:
- 60+ human primary cell-based models of tissue and disease biology
- 150+ clinically relevant protein biomarkers
- 4,500+ reference molecule profiles in the proprietary BioMAP Reference Database
- A suite of bioinformatics-based approaches for mechanism class characterization and predictive efficacy and safety determinations
Watch our animation to learn more about this powerful translational biology approach.
BioMAP Phenotypic Profiling & Screening Accelerates Candidates from Testing to Therapies
Unparalleled Comparison and Prioritization
- Benchmarking to internal assets and approved standards of care
- Prioritization and rank ordering of candidate small molecules and biologics
- Lead optimization and screening of test agents based on physiologically relevant and predictive disease and tissue biology
- Combination testing to evaluate drug combinations before moving in vivo.
Unmatched Characterization
- Mechanism-of-action identification based on a systems biology approach, and the only protein biomarker profile database of its kind
- Indication selection to ensure the best return on investment for a given molecule
- Repositioning and repurposing to breathe new life into old assets
- Safety and cytotoxicity screening to identify off-target effects without bias, and for prediction of adverse events with BioMAP Toxicity Signature Analysis
